HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
pirmagrel
structure given in first source
Also Known As:
CGS 13080; CGS-13080; imidazol(1,5-a)pyridine-5-hexanoic acid; Imidazo(1,5-a)pyridine-5-hexanoic acid
Networked:
16
relevant articles (
0
outcomes,
2
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Imidazoles: 150
pirmagrel: 16
Pyridines: 88
pirmagrel: 16
Experts
1.
Ding, Z Q
: 1 article (09/2002)
2.
Gallery, E D M
: 1 article (09/2002)
3.
Ng, B
: 1 article (09/2002)
4.
Rowe, J
: 1 article (09/2002)
5.
Sinosich, M J
: 1 article (09/2002)
Related Diseases
1.
Pre-Eclampsia (Preeclampsia)
09/01/2002 - "
This study confirmed that cytotrophoblasts from pre-eclamptic women had increased thromboxane production and showed that pirmagrel, at the relatively low dose of 0.001 microM, was able to normalize the imbalance of thromboxane and prostacylin production and may therefore warrant further investigation as a treatment for pre-eclampsia.
"
2.
Sudden Death
06/01/1987 - "
This study was designed to determine the in vivo effects of a phosphodiesterase inhibitor (HL 725) in combination with a thromboxane synthase inhibitor (CGS 13080) or prostacyclin (PGI2) as inhibitors of thrombin-induced changes in platelet function and prevention of sudden death.
"
3.
Thrombosis (Thrombus)
06/01/1987 - "
Administration of 2 mg/kg of CGS 13080 reduced significantly the mass of the right ventricular thrombus, but did not prevent completely the reduction in the circulating platelet count or death.
"
08/01/1986 - "
Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
"
06/01/1987 - "
After the administration of the combination of CGS 13080 with HL 725, the thrombocytopenia was transient, the right ventricular thrombus was reduced (P less than .05), and survival increased to 75% (P less than .05).
"
12/01/1988 - "
After 30 min of stable thrombotic occlusion of the femoral artery, sodium heparin (300 U/kg, i.v.) was administered and tPA was infused locally to the site of the thrombus for 30 min at 0.01, 0.10 or 1.0 microgram/kg/min. In other experiments, CGS 13080, a selective thromboxane synthase inhibitor, was administered at a dose of 2 mg/kg i.v., 5 min before tPA was infused and at the end of the 30 min tPA infusion.
"
4.
Myocardial Ischemia (Ischemic Heart Diseases)
09/01/1988 - "
Thus, t-PA and CGS-13080 exert synergistic effects in preserving myocardial integrity in cats subjected to acute myocardial ischemia followed by reperfusion.
"
09/01/1983 - "
A specific inhibitor of thromboxane A2 (TxA2) synthesis, CGS-13080, was studied during acute myocardial ischemia (MI) in cats.
"
5.
Thrombocytopenia (Thrombopenia)
10/01/1983 - "
There were small effects on the thrombocytopenia with CGS 13080 and carboxyheptylimidazole but not with dazoxiben.
"
06/01/1987 - "
After the administration of the combination of CGS 13080 with HL 725, the thrombocytopenia was transient, the right ventricular thrombus was reduced (P less than .05), and survival increased to 75% (P less than .05).
"
Related Drugs and Biologics
1.
Thromboxanes
2.
Thrombin
3.
Epoprostenol (Prostacyclin)
4.
Phosphodiesterase Inhibitors
5.
trequinsin
6.
Thromboxane-A Synthase
7.
pirmagrel
8.
Reactive Oxygen Species (Oxygen Radicals)
9.
Cyclooxygenase Inhibitors
10.
Free Radical Scavengers
Related Therapies and Procedures
1.
Intravenous Infusions